Kadmon (KDMN) – Hot FDA News
-
Kadmon (KDMN) Announces U.S. FDA Grants Full Approval of REZUROCK (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease
-
Kadmon (KDMN) Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease
-
-
-
-
Back to KDMN Stock Lookup